Clinical and economic analysis of different strategies for the treatment of hemophilia A

N. V. Bezditko, O. V. Stasyshyn

Abstract


Although hemophilia A is a rare disease, its treatment is costly, and expenses are mainly related to the cost of factor VIII concentrates.
Aim. To evaluate the clinical and economic feasibility of rFVIIa (NovoSeven®) for the treatment of patients with hemophilia A compared to the schemes based on the use of APCC (Feiba).
Matherials and methods. Clinical and economic analysis was conducted by the “total cost of illness” method using modeling by building a “decision tree”. This study identifies only the direct costs of pharmacotherapy. The cost of a vial
of each of the concentrates analyzed meets the declared value as of December 2016.
Results. The analytical model of the “decision tree” was designed to calculate the costs for the outpatient treatment of mild and moderate bleedings. Due to higher clinical efficacy the use of rFVIIa as the first-line therapy saves 32 % to 42 % in the treatment of a patient; in the conditions of the modern Ukrainian pharmaceutical market it is from UAH 170,326.4 to UAH 252,990.4 (with an adapted variant of therapy) and UAH 291,743.1 in the basic variant. When using rFVIIa as the first-line therapy the costs for life appeared to be lower by approximately 10 % than when taking APCC.
Conclusions. The use of NovoSeven® is more feasible economically and allows both to improve outcomes and to spend financial resources more efficiently to treat these patients.


Keywords


hemophilia; inhibitor; NovoSeven; Feiba; pharmacoeconomic analysis; decision tree

References


The diagnoses and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre

Doctors Organisation / C. Hay, S. Brown, P. Collins et al. // Br. J. Haematol. – 2006. – Vol. 133, Issue 6. – P. 591–605. doi:

1111/j.1365-2141.2006.06087.x

Berntorp, E. Importance of rapid bleeding control in haemophilia complicated by inhibitors / E. Berntorp // Haemophilia. –

– Vol. 17, Issue 1. – P. 11–16. doi: 10.1111/j.1365-2516.2010.02337.x

Odayemi, I. Modelling the economic impact of recombinant activated factor VII and activated prothrombin complex concentrate in

the treatment of a mild to moderate bleed in adults with inhibitors to clotting factor VIII and IX at a comprehensive care centre

in the UK / I. Odayemi, J. Guest // J. of Med. Economics. – 2002. – Vol. 5, Issue 1–4. – P. 51–64. doi: 10.3111/200205051064

Cost of care of haemophilia with inhibitors / M. Di Minno, G. Di Minno, M. Di Capua et al. // Haemophilia. – 2010. – Vol. 16,

Issue 1. – P. e190–e201. doi: 10.1111/j.1365-2516.2009.02100.x

Berntorp, E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors

/ E. Berntorp // Haemophilia. – 2009. – Vol. 15, Issue 1. – P. 3–10. doi: 10.1111/j.1365-2516.2008.01931.x

Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia

and inhibitors: update of our previous experience / J. Schneiderman, E. Rubin, D. Nugent, G. Young // Haemophilia.

– 2007. – Vol. 13, Issue 3. – P. 244–248. doi: 10.1111/j.1365-2516.2007.01451.x

Valentino, L. A. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors / L. A. Valentino // Haemophilia.

– 2009. – Vol. 16, Issue 2. – P. 263–271. doi: 10.1111/j.1365-2516.2009.02126.x

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

/ B. Konkle, L. Ebbesen, E. Erhardtsen et al. // J. of Thrombosis and Haemostasis. – 2007. – Vol. 5, Issue 9. – P. 1904–1913.

doi: 10.1111/j.1538-7836.2007.02663.x

Randomized comparison of prophylaxis and on-demand regimens with Feiba NF in the treatment of haemophilia A and B

with inhibitors / S. Antunes, S. Tangada, O. Stasyshyn et al. // Haemophilia. – 2013. – Vol. 20, Issue 1. – P. 65–72. doi: 10.1111/

hae.12246

Single 270 μg kg-1 – dose rFVIIa vs. standard 90 μg kg-1 – dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia

patients with inhibitors: a randomized comparison / G. Young, F. Shafer, P. Rojas, S. Seremetis // Haemophilia. – 2008. – Vol. 14,

Issue 2. – P. 287–294. doi: 10.1111/j.1365-2516.2007.01601.x

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative

(FENOC) Study / J. Astemark, S. Donfield, D. DiMichele et al. // Blood. – 2007. – Vol. 109, Issue 2. – P. 546–551. doi: 10.1182/

blood-2006-04-017988

Knight, C. Systematic review of efficacy of rFVIIa and aPCC treatment for haemophilia patients with inhibitors / C. Knight,

A. Danø, T. Kennedy-Martin // Advances in Therapy. – 2009. – Vol. 26, Issue 1. – P. 68–88. doi: 10.1007/s12325-008-0135-6

Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors / C. Knight, S. Paisley,

J. Wight, M. Jones // Haemophilia. – 2003. – Vol. 9, Issue 4. – P. 521–540. doi: 10.1046/j.1365-2516.2003.00783.x

Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia

patients with inhibitors / A. Joshi, J. Stephens, V. Munro et al. // Current Med. Res. and Opinion. – 2005. – Vol. 22, Issue 1. –

P. 23–31. doi: 10.1185/030079906x80224

A cost-evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors

in Brazil / M. Ozelo, P. Villaca, J. De Almeida et al. // Haemophilia. – 2007. – Vol. 13, Issue 5. – P. 462–469. doi:

1111/j.1365-2516.2007.01522.x

A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors

in Turkey / S. Dundar, B. Zulfikar, B. Kavaklik et al. // J. of Med. Economics. – 2005. – Vol. 8, Issue 1–4. – P. 45–54. doi:

3111/200508046054

Pharmacoeconomic evaluation of treatment alternatives for mild to moderate bleeding episodes in patients with haemophilia

with inhibitors in Korea. Abstract from the XXI International Society on Thrombosis and Haemostasis Congress 2007

/ S. Yoo, L. Yong, P. Kyu, Y. Woo // J. of Thrombosis and Haemostasis. – 2007. – Vol. 5. – P. 158.

Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate

in mild to moderate bleeds: Haemophilia registry data from the Czech Republic / P. Salaj, M. Penka, P. Smejkal, V. Geierova,

P. Ovesná, P. Brabec et al. // Thrombosis Res. – 2012. – Vol. 129, Issue 5. – P. e233–e237. doi: 10.1016/j.thromres.2012.02.005

Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor

VII in severe haemophilia A patients with inhibitors, in Spain / R. Villarrubia, I. Oyagüez, M. Álvarez-Román et al. // Haemophilia.

– 2015. – Vol. 21, Issue 3. – P. 320–329. doi: 10.1111/hae.12681

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex

Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran / M. Golestania, P. Eshghib, H. Rasekh et

al. // Iranian J. of Pharmaceutical Res. – 2016. – Vol. 15. – P. 669–677.

Jo, C. Cost-of-illness studies: concepts, scopes, and methods / C. Jo // Clinical and Molecular Hepatol. – 2014. – Vol. 20, Issue 4. –

P. 327. doi: 10.3350/cmh.2014.20.4.327

Cost-of-illness Studies / E. Akobundu, J. Ju, L. Blatt, C. Mullins // Pharmacoeconomics. – 2006. – Vol. 24, Issue 9. – P. 869–890.

doi: 10.2165/00019053-200624090-00005

Фармакоекономіка : навч. посіб. для студентів ВНЗ / Л. Яковлєва, Н. Бездітко, О. Герасимова та ін. – Вінниця : Нова

книга, 2009. – 208 с.

Briggs, A. Decision Modelling for Health Economic Evaluation / A. Briggs, M. Sculpher, K. Claxton // Handbooks in Health

Economic Evaluation. – Oxford University Press, 2006. – P. 256.

Реєстр оптово-відпускних цін на лікарські засоби [Електронний ресурс]. – 23.12.2016. – Режим доступу до ресурсу :

http://www.moz.gov.ua/ua/portal/register_prices_drugs.

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study / E. Santagostino,

M. Mancuso, A. Rocino et al. // Brit. J. of Haematol. – 2005. – Vol. 130, Issue 3. – P. 422–427. doi: 10.1111/j.1365-2141.2005.05605.x

Gouw, S. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the

CANAL cohort study / S. Gouw, J. van der Bom, H. van den Berg // Blood. – 2007. – Vol. 109, Issue 11. – P. 4648–4654. doi:

org/10.1182/blood-2006-11-056291


GOST Style Citations


1. Hay, C. R. M., Brown, S., Collins, P. W., Keeling, D. M., Liesner, R. (2006). The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. British Journal of Haematology, 133 (6), 591–605. doi: 10.1111/j.1365-2141.2006.06087.x

2. Berntorp, E. (2010). Importance of rapid bleeding control in haemophilia complicated by inhibitors. Haemophilia, 17 (1), 11–16. doi: 10.1111/j.1365-2516.2010.02337.x

3. Odeyemi, I. A. O., Guest, J. F. (2002). Modelling the economic impact of recombinant activated Factor VII and activated prothrombin-complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX at a comprehensive care centre in the UK. Journal of Medical Economics, 5 (1-4), 51–64. doi: 10.3111/200205051064

4. Minno, M. N. D. D., Minno, G. D., Capua, M. D., Cerbone, A. M., Coppola, A. (2010). Cost of care of haemophilia with inhibitors. Haemophilia, 16 (1), e190–e201. doi: 10.1111/j.1365-2516.2009.02100.x

5. Berntorp, E. (2009). Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia, 15 (1), 3–10. doi: 10.1111/j.1365-2516.2008.01931.x

6. Schneiderman, J., Rubin, E., Nugent, D. J., Young, G. (2007). Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia, 13 (3), 244–248. doi: 10.1111/j.1365-2516.2007.01451.x

7. Valentino, L. A. (2009). Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia, 16 (2), 263–271. doi: 10.1111/j.1365-2516.2009.02126.x

8. Konkle, B. A., Ebbesen, L. S., Erhardtsen, E., Bianco, R. P., Lissitchkov, T., Rusen, L., Serban, M. A. (2007). Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. Journal of Thrombosis and Haemostasis, 5 (9), 1904–1913. doi: 10.1111/j.1538-7836.2007.02663.x

9. Antunes, S. V., Tangada, S., Stasyshyn, O., Mamonov, V., Phillips, J., Guzman-Becerra, N., Wong, W. Y. (2013). Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia, 20 (1), 65–72. doi: 10.1111/hae.12246

10. Young, G., Shafer, F. E., Rojas, P., Seremetis, S. (2008). Single 270 μg kg−1-dose rFVIIa vs. standard 90 μg kg−1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia, 14 (2), 287–294. doi: 10.1111/j.1365-2516.2007.01601.x

11. Astermark, J., Donfield, S. M., DiMichele, D. M., Gringeri, A., Gilbert, S. A., Waters, J. (2007). A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood, 109 (2), 546–551. doi: 10.1182/blood-2006-04-017988

12. Knight, C., Danø, A. M., Kennedy-Martin, T. (2009). Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors. Advances in Therapy, 26 (1), 68–88. doi: 10.1007/s12325-008-0135-6

13. Knight, C., Paisley, S., Wight, J., Jones, M. L. (2003). Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia, 9 (4), 521–540. doi: 10.1046/j.1365-2516.2003.00783.x

14. Joshi, A. V., Stephens, J. M., Munro, V., Mathew, P., Botteman, M. F. (2005). Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Current Medical Research and Opinion, 22 (1), 23–31. doi: 10.1185/030079906x80224

15. Ozelo, M. C., Villaça, P. R., De Almeida, J. O. S. C., Bueno, T. M. F., De Miranda, P. A. P., Hart, W. M., Karamalis, M. (2007). A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil. Haemophilia, 13 (5), 462–469. doi: 10.1111/j.1365-2516.2007.01522.x

16. Dundar, S., Zülfikar, B., Kavakli, K., Gönen, C., Zülfikar, H., Yilmaz, D., Karamalis, M. (2005). A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey. Journal of Medical Economics, 8 (1-4), 46–54. doi: 10.3111/200508046054

17. Yoo, S., Yong, L., Kyu, P., Woo, Y. (2007). Pharmacoeconomic evaluation of treatment alternatives for mild to moderate bleeding episodes in patients with haemophilia with inhibitors in Korea. Abstract from the XXI International Society on Thrombosis and Haemostasis Congress 2007. Journal of Thrombosis and Haemostasis, 5, 158.

18. Salaj, P., Penka, M., Smejkal, P., Geierova, V., Ovesná, P., Brabec, P. et al. (2012). Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic. Thrombosis Research, 129 (5), e233–e237. doi: 10.1016/j.thromres.2012.02.005

19. Villarrubia, R., Oyagüez, I., Álvarez-Román, M. T., Mingot-Castellano, M. E., Parra, R., Casado, M. A. (2015). Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain. Haemophilia, 21 (3), 320–329. doi: 10.1111/hae.12681

20. Golestania, M., Eshghib, P., Rasekh, H. et al. (2016) Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran. Iranian Journal of Pharmaceutical Research, 15, 669–677.

21. Jo, C. (2014). Cost-of-illness studies: concepts, scopes, and methods. Clinical and Molecular Hepatology, 20 (4), 327. doi: 10.3350/cmh.2014.20.4.327

22. Akobundu, E., Ju, J., Blatt, L., Mullins, C. D. (2006). Cost-of-Illness Studies. PharmacoEconomics, 24 (9), 869–890. doi: 10.2165/00019053-
200624090-00005

23. Yakovleva, L., Bezditko, N., Gerasimova, O. et al. (2009). Farmacoeconomika–Pharmacoeconomic. Vinnytsia: Nova knyha, 208.

24. Briggs, A., Sculpher, M., Claxton, K. (2006). Decision Modelling for Health Economic Evaluation. Handbooks in Health Economic Evaluation. Oxford University Press, 256.

25. The register of wholesale selling prices for medicines. (2016). Available at: http://www.moz.gov.ua/ua/portal/register_prices_drugs.

26. Santagostino, E., Mancuso, M. E., Rocino, A., Mancuso, G., Mazzucconi, M. G., Tagliaferri, A., Mannucci, P. M. (2005). Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. British Journal of Haematology, 130 (3), 422–427. doi: 10.1111/j.1365-2141.2005.05605.x

27. Gouw, S. C., van der Bom, J. G., Marijke van den Berg, H. (2007). Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood, 109 (11), 4648–4654. doi: 10.1182/blood-2006-11-056291





DOI: https://doi.org/10.24959/cphj.17.1414

Abbreviated key title: Klìn. farm.

ISSN 2518-1572 (Online), ISSN 1562-725X (Print)